MS Trial Alert: Investigators in Alabama Seeking Participants for Physical Therapy Study in MS
Aug 13, 2010
Summary: Investigators at the University of Alabama at Birmingham are recruiting 66 people with relapsing-remitting, secondary-progressive, or primary-progressive MS to participate in a study comparing the effectiveness of two types of physical therapy for increasing movement (improving nonuse) of the arm in MS.
Summary: Investigators at the University of Alabama at Birmingham are recruiting 66 people with relapsing-remitting, secondary-progressive, or primary-progressive MS to participate in a study comparing the effectiveness of two types of physical therapy for increasing movement (improving nonuse) of the arm in MS.
MS Trial Alert: Investigators Studying ELND002, Subcutaneous Drug in 125 People with Relapsing MS
Aug 13, 2010
Summary: Investigators are recruiting 125 people with relapsing MS in the United States and Canada to determine the safety and effectiveness of ELND002, a variation of an alpha-4-integrin inhibitor delivered via injection under the skin. Elan Pharmaceuticals is sponsoring the study.
Summary: Investigators are recruiting 125 people with relapsing MS in the United States and Canada to determine the safety and effectiveness of ELND002, a variation of an alpha-4-integrin inhibitor delivered via injection under the skin. Elan Pharmaceuticals is sponsoring the study.
MS Trial Alert: Investigators Recruiting Worldwide for Phase II Study of Oral ACT-128800
Aug 02, 2010
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd.
Investigators are recruiting 400 people with relapsing-remitting MS for a study evaluating three doses of ACT-128800, an oral compound that affects immune function, versus placebo. The study sponsor is Actelion Pharmaceuticals, Ltd.
Recent Papers Highlight Difficulty of Studying Long-Term Impact on Progression of MS Disease-Modifying Therapies
Jul 29, 2010
Scores of research papers from well-controlled clinical trials demonstrate that the MS disease-modifying therapies significantly reduce MS relapses and disease progression, and improve quality of life. However, well-controlled research proving that these drugs can delay the progression of disability over the long term is lacking, which is illustrated in a recently reported British-based study. This article reviews this and other studies that provide additional important data regarding disease-modifying therapies.
Scores of research papers from well-controlled clinical trials demonstrate that the MS disease-modifying therapies significantly reduce MS relapses and disease progression, and improve quality of life. However, well-controlled research proving that these drugs can delay the progression of disability over the long term is lacking, which is illustrated in a recently reported British-based study. This article reviews this and other studies that provide additional important data regarding disease-modifying therapies.
FDA Gives Priority Review Status to Application for Oral Cladribine to Treat Relapsing Multiple Sclerosis
Jul 28, 2010
EMD Serono has announced that the U.S. Food and Drug Administration has accepted and given Priority Review to its application seeking approval to market cladribine as an oral disease-modifying therapy for relapsing forms of MS.
EMD Serono has announced that the U.S. Food and Drug Administration has accepted and given Priority Review to its application seeking approval to market cladribine as an oral disease-modifying therapy for relapsing forms of MS.
*
*
***********************************************************
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
(This will take 20-25 seconds and will empower you
with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************
0 comments:
Post a Comment